Bergenbio Asa Stock Analysis
| BRRGF Stock | USD 97.09 0.00 0.00% |
BerGenBio ASA holds a debt-to-equity ratio of 0.002. BerGenBio ASA's financial risk is the risk to BerGenBio ASA stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
BerGenBio ASA's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. BerGenBio ASA's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps BerGenBio Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect BerGenBio ASA's stakeholders.
For many companies, including BerGenBio ASA, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for BerGenBio ASA, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, BerGenBio ASA's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that BerGenBio ASA's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which BerGenBio ASA is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of BerGenBio ASA to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, BerGenBio ASA is said to be less leveraged. If creditors hold a majority of BerGenBio ASA's assets, the Company is said to be highly leveraged.
BerGenBio ASA is overvalued with Real Value of 60.44 and Hype Value of 97.09. The main objective of BerGenBio ASA pink sheet analysis is to determine its intrinsic value, which is an estimate of what BerGenBio ASA is worth, separate from its market price. There are two main types of BerGenBio ASA's stock analysis: fundamental analysis and technical analysis.
The BerGenBio ASA pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and BerGenBio ASA's ongoing operational relationships across important fundamental and technical indicators.
BerGenBio |
BerGenBio Pink Sheet Analysis Notes
About 35.0% of the company shares are held by company insiders. The book value of BerGenBio ASA was currently reported as 1.86. The company recorded a loss per share of 0.35. BerGenBio ASA had not issued any dividends in recent years. BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. The company was incorporated in 2007 and is headquartered in Bergen, Norway. Bergenbio is traded on OTC Exchange in the United States.The quote for BerGenBio ASA is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on BerGenBio ASA please contact the company at 47 55 96 11 59 or go to https://www.bergenbio.com.BerGenBio ASA Investment Alerts
| BerGenBio ASA is way too risky over 90 days horizon | |
| BerGenBio ASA appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 774 K. Net Loss for the year was (309.36 M) with profit before overhead, payroll, taxes, and interest of 774 K. | |
| BerGenBio ASA has accumulated about 509.41 M in cash with (303.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.77. | |
| Roughly 35.0% of the company shares are held by company insiders |
BerGenBio Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 207.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BerGenBio ASA's market, we take the total number of its shares issued and multiply it by BerGenBio ASA's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 17th of February 2026, BerGenBio ASA shows the Risk Adjusted Performance of 0.1385, mean deviation of 62.64, and Standard Deviation of 179.59. BerGenBio ASA technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm BerGenBio ASA risk adjusted performance, standard deviation, as well as the relationship between the Standard Deviation and maximum drawdown to decide if BerGenBio ASA is priced correctly, providing market reflects its regular price of 97.09 per share. Given that BerGenBio ASA has variance of 32253.81, we suggest you to validate BerGenBio ASA's prevailing market performance to make sure the company can sustain itself at a future point.BerGenBio ASA Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BerGenBio ASA middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BerGenBio ASA. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
BerGenBio ASA Predictive Daily Indicators
BerGenBio ASA intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BerGenBio ASA pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BerGenBio ASA Forecast Models
BerGenBio ASA's time-series forecasting models are one of many BerGenBio ASA's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BerGenBio ASA's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.BerGenBio ASA Debt to Cash Allocation
Many companies such as BerGenBio ASA, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
BerGenBio ASA has accumulated 1.02 M in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. BerGenBio ASA has a current ratio of 7.88, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BerGenBio ASA until it has trouble settling it off, either with new capital or with free cash flow. So, BerGenBio ASA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BerGenBio ASA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BerGenBio to invest in growth at high rates of return. When we think about BerGenBio ASA's use of debt, we should always consider it together with cash and equity.BerGenBio ASA Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the BerGenBio ASA's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of BerGenBio ASA, which in turn will lower the firm's financial flexibility.About BerGenBio Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how BerGenBio ASA prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BerGenBio shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as BerGenBio ASA. By using and applying BerGenBio Pink Sheet analysis, traders can create a robust methodology for identifying BerGenBio entry and exit points for their positions.
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. The company was incorporated in 2007 and is headquartered in Bergen, Norway. Bergenbio is traded on OTC Exchange in the United States.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding BerGenBio ASA to your portfolios without increasing risk or reducing expected return.Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
Complementary Tools for BerGenBio Pink Sheet analysis
When running BerGenBio ASA's price analysis, check to measure BerGenBio ASA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BerGenBio ASA is operating at the current time. Most of BerGenBio ASA's value examination focuses on studying past and present price action to predict the probability of BerGenBio ASA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BerGenBio ASA's price. Additionally, you may evaluate how the addition of BerGenBio ASA to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |